Monograph
J07BF03 - Poliomyelitis, Trivalent, Inactivated, Whole Virus |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the poliomyelitis, trivalent, inactivated, whole virus vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated polio virus type 1, 2 and 3.
Therapeutic characteristics
The poliomyelitis vaccine is indicated for the active immunization against poliomyelitis in infants, children and adults, for both primary immunization (2 or 3 doses) and for following booster doses. It is administered by intramuscular or deep subcutaneous injection.
Metabolism and pharmacokinetics
The poliomyelitis vaccine is not metabolized by the cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Imovax Polio. (Last edition: 31.06. 2014).
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Poliomyelitisvaccin 
Imovax Polio 
Imovax Polio Jerina 
Poliomyelitis Vaccine 
Imovax Polio · Picovax · Poliovaccine 
Imovax Polio 
Imovax Polio 
Imovax-Polio 
Imovax Polio 
Imovax Polio · Veropol 
Imovax Polio
© NAPOS 2025